- Conditions
- Primary Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost, Timolol 0.5%, Placebo Ocular Insert, Placebo Eye Drops
- Drug · Device
- Lead sponsor
- ForSight Vision5, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 10
- States / cities
- Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–36
of 36
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- 1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran), 1 drop of 1.5% SYL040012 (bamosiran), 1 drop of 0.5 % timolol maleate
- Drug
- Lead sponsor
- Sylentis, S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 4
- States / cities
- Artesia, California • Petaluma, California • Morrow, Georgia + 1 more
- Conditions
- Glaucoma
- Interventions
- Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, placebo eye drops
- Drug · Procedure · Other
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Dothan, Alabama
- Conditions
- Cataract, Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL
- Drug · Device
- Lead sponsor
- SpyGlass Pharma, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Glaucoma and Ocular Hypertension
- Interventions
- DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 12 Months and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Burbank, California + 40 more
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension
- Interventions
- DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 41
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 34 more
- Conditions
- Hemangioma
- Interventions
- topical timolol maleate, Pulsed dye laser
- Drug · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- Up to 3 Months
- Enrollment
- 126 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Glaucoma Open-Angle Primary, Ocular Hypertension
- Interventions
- H-1337 0.6%, H-1337 1.0%, H-1337 Placebo, Timolol 0.5%
- Drug
- Lead sponsor
- D. Western Therapeutics Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Glendale, California • Colorado Springs, Colorado • Lakeland, Florida + 6 more
- Conditions
- Glaucoma
- Interventions
- BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5%
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 14
- States / cities
- Glendale, California • Newport Beach, California • Pasadena, California + 11 more
- Conditions
- Glaucoma
- Interventions
- Travoprost 0.004% Ophthalmic Solution (Travatan), Timolol 0.5% Ophthalmic Solution (Timoptic)
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Ocular Hypertension, Open Angle Glaucoma
- Interventions
- BOL-303259-X, Timolol maleate
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Cataract, Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost Implant System (High Dose), Bimatoprost Implant System (Low Dose), Timolol Maleate Ophthalmic Solution, 0.5%, Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL, SpyGlass IOL
- Drug · Device
- Lead sponsor
- SpyGlass Pharma, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Glendale, Arizona